JP2020523390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523390A5 JP2020523390A5 JP2019569457A JP2019569457A JP2020523390A5 JP 2020523390 A5 JP2020523390 A5 JP 2020523390A5 JP 2019569457 A JP2019569457 A JP 2019569457A JP 2019569457 A JP2019569457 A JP 2019569457A JP 2020523390 A5 JP2020523390 A5 JP 2020523390A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- cancer
- optionally substituted
- neuropathy
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims 32
- 208000033808 peripheral neuropathy Diseases 0.000 claims 22
- 201000001119 neuropathy Diseases 0.000 claims 18
- 230000007823 neuropathy Effects 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 8
- 230000000973 chemotherapeutic effect Effects 0.000 claims 8
- 208000004296 neuralgia Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 208000001640 Fibromyalgia Diseases 0.000 claims 4
- 208000007514 Herpes zoster Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000005233 alkylalcohol group Chemical group 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000004371 toothache Diseases 0.000 claims 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 206010016059 Facial pain Diseases 0.000 claims 2
- 208000027109 Headache disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 206010029216 Nervousness Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000004983 Phantom Limb Diseases 0.000 claims 2
- 206010056238 Phantom pain Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000026062 Tissue disease Diseases 0.000 claims 2
- 206010045171 Tumour pain Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000018180 degenerative disc disease Diseases 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000030212 nutrition disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000003497 sciatic nerve Anatomy 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010011703 Cyanosis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 0 CCC(CC)(C1)Oc(ccc(*)c2)c2C1=O Chemical compound CCC(CC)(C1)Oc(ccc(*)c2)c2C1=O 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ccccn1 Chemical compound Cc1ccccn1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 4
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N Cc1ccncc1 Chemical compound Cc1ccncc1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- SDEBHTVHSXUSLH-UHFFFAOYSA-N 3-bromo-5-(2-methoxyphenyl)-1,2,4-thiadiazole Chemical compound COc1ccccc1-c1nc(Br)ns1 SDEBHTVHSXUSLH-UHFFFAOYSA-N 0.000 description 2
- HCLVAGHVWIQPHE-UHFFFAOYSA-N C(C)C1(OC2=CC=C(C=C2C(C1)=O)C1=NSC(=N1)C1=C(C=CC=C1)OC)CC Chemical compound C(C)C1(OC2=CC=C(C=C2C(C1)=O)C1=NSC(=N1)C1=C(C=CC=C1)OC)CC HCLVAGHVWIQPHE-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical compound CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MFXNOVNAXVVJRF-UHFFFAOYSA-N 1-cyclopentyl-N'-hydroxybenzotriazole-5-carboximidamide Chemical compound C1(CCCC1)N1N=NC2=C1C=CC(=C2)C(=N)NO MFXNOVNAXVVJRF-UHFFFAOYSA-N 0.000 description 1
- GPTAGRLOOGHGHU-UHFFFAOYSA-N 3-(1-cyclopentylbenzotriazol-5-yl)-5-(3-methylphenyl)-1,2,4-oxadiazole Chemical compound CC1=CC=CC(C=2ON=C(N=2)C=2C=C3N=NN(C3=CC=2)C2CCCC2)=C1 GPTAGRLOOGHGHU-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- LCXTYIGYHHNNPW-UHFFFAOYSA-N 5-(2-bromophenyl)-3-(1-cyclopentylbenzotriazol-5-yl)-1,2,4-oxadiazole Chemical compound BrC1=CC=CC=C1C1=NC(C=2C=C3N=NN(C3=CC=2)C2CCCC2)=NO1 LCXTYIGYHHNNPW-UHFFFAOYSA-N 0.000 description 1
- QMXNOVMHGDOLNP-UHFFFAOYSA-N C1(=CC=CC=C1)C=1N=C(OC=1)C1=CC2=C(N(N=N2)C(C)C)C=C1 Chemical compound C1(=CC=CC=C1)C=1N=C(OC=1)C1=CC2=C(N(N=N2)C(C)C)C=C1 QMXNOVMHGDOLNP-UHFFFAOYSA-N 0.000 description 1
- CWNHSTHRAWCRPI-UHFFFAOYSA-N CC(C)(C[n]1nnc2c1ccc(-c1nc(-c(cc(C)cc3)c3OC)n[o]1)c2)O Chemical compound CC(C)(C[n]1nnc2c1ccc(-c1nc(-c(cc(C)cc3)c3OC)n[o]1)c2)O CWNHSTHRAWCRPI-UHFFFAOYSA-N 0.000 description 1
- IWTLAALJPRWRCY-UHFFFAOYSA-N CC(C)(C[n]1nnc2c1ccc(-c1nc(-c(cc3)c(C)cc3OC)n[o]1)c2)O Chemical compound CC(C)(C[n]1nnc2c1ccc(-c1nc(-c(cc3)c(C)cc3OC)n[o]1)c2)O IWTLAALJPRWRCY-UHFFFAOYSA-N 0.000 description 1
- VXPCMPWKRCZJLB-UHFFFAOYSA-N CC(C)C1CCOCC1 Chemical compound CC(C)C1CCOCC1 VXPCMPWKRCZJLB-UHFFFAOYSA-N 0.000 description 1
- FWRDVZKENHXTJF-UHFFFAOYSA-O CC(C)N1[NH2+]Nc2c1ccc(-c1nc(-c3ccccc3C)n[o]1)c2 Chemical compound CC(C)N1[NH2+]Nc2c1ccc(-c1nc(-c3ccccc3C)n[o]1)c2 FWRDVZKENHXTJF-UHFFFAOYSA-O 0.000 description 1
- MUSRMUUAKCIELW-UHFFFAOYSA-N CC(C)[n]1nnc2c1ccc(-c1nc(-c3c4OCCCc4ccc3)n[o]1)c2 Chemical compound CC(C)[n]1nnc2c1ccc(-c1nc(-c3c4OCCCc4ccc3)n[o]1)c2 MUSRMUUAKCIELW-UHFFFAOYSA-N 0.000 description 1
- PNNITHGQTGQWGS-UHFFFAOYSA-N CCC(CC)(C1)Oc(ccc(-c2nc(-c3c[nH]nc3)n[o]2)c2)c2C1=O Chemical compound CCC(CC)(C1)Oc(ccc(-c2nc(-c3c[nH]nc3)n[o]2)c2)c2C1=O PNNITHGQTGQWGS-UHFFFAOYSA-N 0.000 description 1
- MLAXEZHEGARMPE-UHFFFAOYSA-N CCCc1cccnc1 Chemical compound CCCc1cccnc1 MLAXEZHEGARMPE-UHFFFAOYSA-N 0.000 description 1
- DSFNLOOPOZXDNO-UHFFFAOYSA-N CNSC(c1ccccc1OC)=N Chemical compound CNSC(c1ccccc1OC)=N DSFNLOOPOZXDNO-UHFFFAOYSA-N 0.000 description 1
- SYNCTJISHRLZSJ-UHFFFAOYSA-N N#Cc1cc(-c2nc(-c3cc4n[o]nc4cc3)n[o]2)ccc1NCC1CC1 Chemical compound N#Cc1cc(-c2nc(-c3cc4n[o]nc4cc3)n[o]2)ccc1NCC1CC1 SYNCTJISHRLZSJ-UHFFFAOYSA-N 0.000 description 1
- VIJLBBNQXHJLGU-UHFFFAOYSA-N Nc(cc(cc1)-c2n[o]c(-c(cccc3)c3Br)n2)c1N(C1CCCC1)N Chemical compound Nc(cc(cc1)-c2n[o]c(-c(cccc3)c3Br)n2)c1N(C1CCCC1)N VIJLBBNQXHJLGU-UHFFFAOYSA-N 0.000 description 1
- JJSVNZRGHYXMES-UHFFFAOYSA-N Nc(cc(cc1)C(NO)=N)c1N(C1CCCC1)N Chemical compound Nc(cc(cc1)C(NO)=N)c1N(C1CCCC1)N JJSVNZRGHYXMES-UHFFFAOYSA-N 0.000 description 1
- XRXMNWGCKISMOH-UHFFFAOYSA-N OC(c(cccc1)c1Br)=O Chemical compound OC(c(cccc1)c1Br)=O XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910001544 silver hexafluoroantimonate(V) Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023046107A JP2023078375A (ja) | 2017-06-14 | 2023-03-23 | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519575P | 2017-06-14 | 2017-06-14 | |
| US62/519,575 | 2017-06-14 | ||
| PCT/US2018/036989 WO2018231745A1 (en) | 2017-06-14 | 2018-06-12 | Compounds for modulating s1p1 activity and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023046107A Division JP2023078375A (ja) | 2017-06-14 | 2023-03-23 | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523390A JP2020523390A (ja) | 2020-08-06 |
| JP2020523390A5 true JP2020523390A5 (https=) | 2021-07-26 |
| JP7252908B2 JP7252908B2 (ja) | 2023-04-05 |
Family
ID=64660688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569457A Active JP7252908B2 (ja) | 2017-06-14 | 2018-06-12 | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
| JP2023046107A Pending JP2023078375A (ja) | 2017-06-14 | 2023-03-23 | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023046107A Pending JP2023078375A (ja) | 2017-06-14 | 2023-03-23 | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11912693B2 (https=) |
| EP (1) | EP3638235A4 (https=) |
| JP (2) | JP7252908B2 (https=) |
| KR (1) | KR102892521B1 (https=) |
| CN (1) | CN110831593A (https=) |
| AU (2) | AU2018282747B2 (https=) |
| CA (1) | CA3066423A1 (https=) |
| IL (1) | IL271149B2 (https=) |
| WO (1) | WO2018231745A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| CN110446495B (zh) * | 2017-02-17 | 2023-09-05 | 特维娜有限公司 | 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| JP7252908B2 (ja) | 2017-06-14 | 2023-04-05 | トレベナ・インコーポレイテッド | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| WO2020132493A1 (en) * | 2018-12-21 | 2020-06-25 | Indiana University Research And Technology Corporation | Compositions and methods for suppressing and/or treating hiv-infection and/or a related clinical condition thereof |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| CA3143103A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
| MX2021015511A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| EP4007497A4 (en) * | 2019-08-01 | 2023-11-29 | Duke University | ß-ARRESTIN-MODULATING COMPOUNDS AND METHODS OF USING SAME |
| AU2020341464A1 (en) * | 2019-09-05 | 2022-04-21 | Trevena, Inc. | Methods of treating epilepsy using the same |
| MX2022005766A (es) * | 2019-11-19 | 2022-08-08 | Trevena Inc | Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1). |
| EP4126829B1 (en) | 2020-03-27 | 2026-02-18 | Receptos LLC | Sphingosine 1 phosphate receptor modulators |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| AU2022221336A1 (en) * | 2021-02-10 | 2023-08-24 | Icahn School Of Medicine At Mount Sinai | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| AU2023235313A1 (en) | 2022-03-17 | 2024-10-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2025245484A1 (en) * | 2024-05-23 | 2025-11-27 | Thymofox Inc. | Foxn1 activators |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000003681A2 (en) | 1998-07-16 | 2000-01-27 | Axys Pharmaceuticals, Inc. | Process for the synthesis of benzopyran derivatives |
| DE60205974T2 (de) * | 2001-04-04 | 2006-06-29 | Pfizer Products Inc., Groton | Neue Benzotriazole mit entzündungshemmender Wirkung |
| WO2004018462A1 (en) * | 2002-08-23 | 2004-03-04 | Celltech R & D Limited | Quinazolinone derivatives |
| WO2004022554A1 (en) * | 2002-09-07 | 2004-03-18 | Celltech R & D Limited | Quinazolinone derivatives |
| AU2003256003A1 (en) * | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
| EP2402323A3 (en) | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| RU2426731C2 (ru) | 2005-12-23 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | Производные арил-изоксазоло-4-ил-оксадиазола |
| PL2003132T3 (pl) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| US7803940B2 (en) * | 2006-11-24 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases |
| PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| KR101582910B1 (ko) * | 2008-05-14 | 2016-01-08 | 더 스크립스 리서치 인스티튜트 | 스핑고신 포스페이트 수용체의 신규한 모듈레이터 |
| EP2304366A2 (en) | 2008-05-30 | 2011-04-06 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
| EP2297140A4 (en) | 2008-06-06 | 2012-05-02 | Abbott Lab | NOVEL 1,2,4-OXADIAZOLE COMPOUNDS AND METHODS OF USE |
| TW201000099A (en) * | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| WO2010043000A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators and their use thereof |
| TW201116212A (en) * | 2009-10-29 | 2011-05-16 | Du Pont | Heterobicycle-substituted azolyl benzene fungicides |
| BR112012023974A2 (pt) * | 2010-04-08 | 2017-09-26 | Merck Sharp & Dohme | composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. |
| WO2011146089A1 (en) * | 2010-05-21 | 2011-11-24 | Abbott Laboratories | Modulators of 5-ht receptors and methods of use thereof |
| EP2635573B1 (en) | 2010-11-03 | 2014-10-01 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| CN106038567A (zh) | 2010-11-08 | 2016-10-26 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| US20140051679A1 (en) * | 2011-10-12 | 2014-02-20 | Univeristy Health Networks | Kinase inhibitors and method of treating cancer with same |
| EP2671881A1 (en) | 2012-06-07 | 2013-12-11 | Syngenta Participations AG. | Pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives |
| US9403845B2 (en) * | 2012-08-20 | 2016-08-02 | Syngenta Participations Ag | Pesticidally active pyridyl- and pyrimidyl- substituted pyrazole derivatives |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| EP2853532B1 (en) * | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| AU2017216429B2 (en) | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| JP7252908B2 (ja) | 2017-06-14 | 2023-04-05 | トレベナ・インコーポレイテッド | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
| AU2020341464A1 (en) | 2019-09-05 | 2022-04-21 | Trevena, Inc. | Methods of treating epilepsy using the same |
| MX2022005766A (es) | 2019-11-19 | 2022-08-08 | Trevena Inc | Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1). |
-
2018
- 2018-06-12 JP JP2019569457A patent/JP7252908B2/ja active Active
- 2018-06-12 AU AU2018282747A patent/AU2018282747B2/en active Active
- 2018-06-12 IL IL271149A patent/IL271149B2/en unknown
- 2018-06-12 WO PCT/US2018/036989 patent/WO2018231745A1/en not_active Ceased
- 2018-06-12 EP EP18818411.3A patent/EP3638235A4/en active Pending
- 2018-06-12 CA CA3066423A patent/CA3066423A1/en active Pending
- 2018-06-12 KR KR1020207000399A patent/KR102892521B1/ko active Active
- 2018-06-12 CN CN201880044277.0A patent/CN110831593A/zh active Pending
- 2018-06-12 US US16/613,152 patent/US11912693B2/en active Active
-
2023
- 2023-03-23 JP JP2023046107A patent/JP2023078375A/ja active Pending
- 2023-04-05 US US18/296,018 patent/US20230234946A1/en active Pending
-
2024
- 2024-04-15 AU AU2024202449A patent/AU2024202449A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523390A5 (https=) | ||
| JP7672451B2 (ja) | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 | |
| CN105461695B (zh) | 嘧啶或三嗪衍生物及其制备方法和用途 | |
| WO2021106231A1 (en) | A compound having inhibitory activity against kras g12d mutation | |
| WO2014125408A2 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
| WO2022166469A1 (zh) | Fgfr激酶抑制剂及其应用 | |
| CN110869017B (zh) | 细胞凋亡信号调节激酶1抑制剂及其使用方法 | |
| JP6691115B2 (ja) | コパンリシブおよびそれの二塩酸塩の合成 | |
| EP2145877B1 (en) | Aurora Kinase inhibitors | |
| JP2006520794A (ja) | 化合物 | |
| TW200911789A (en) | New chemical compounds | |
| WO2023066283A1 (en) | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof | |
| WO2008147831A1 (en) | Anthranilamides | |
| TW202317544A (zh) | 吡啶酮mk2抑制劑及其用途 | |
| TW201625633A (zh) | 科帕利普（ｃｏｐａｎｌｉｓｉｂ）及其二鹽酸鹽之合成 | |
| WO2024017201A1 (en) | Cbl-b inhibitors and methods of uses thereof | |
| CN116157128A (zh) | 吡唑并哒嗪酮化合物、其药物组合物及其用途 | |
| WO2024131939A1 (en) | Cbl-b inhibitors and methods of uses thereof | |
| JP2025128388A (ja) | キナーゼ阻害剤を調製するためのプロセス | |
| JP2022529309A (ja) | ピラゾリル－アミノ－ピリミジニル誘導体のベンズエーテルとアニリン、およびその組成物と方法 | |
| WO2008045834A2 (en) | Kinase inhibitors | |
| JP2009520782A (ja) | 化合物 | |
| CN120322230A (zh) | 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合 | |
| CN111491923B (zh) | N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 | |
| WO2014125410A1 (en) | N-substituted heterocyclic derivatives as kinase inhibitors |